GABA receptors — research review 1

...and one of the most fundamental systems in our nervous system, crucial for pain regulation, is the GABA receptor pathway. It's the main inhibitory system, and when we boost its activity, it generally calms down pain signals.

So, how does this relate to aging and overall mortality? Is it about the receptor itself?

Not directly the receptor, but rather what happens when this system isn't functioning optimally, leading to unrelieved chronic pain. The aging connection here is quite striking.

You mean chronic pain impacts biological aging?

Exactly. Evidence suggests unrelieved pain actually accelerates biological aging. For example, a study in GeroScience in 2025, PMID 39847262, found that painful diabetic neuropathy is associated with accelerated epigenetic aging and telomere shortening compared with painless neuropathy.

That’s a significant link. So, the chronic inflammation and stress from ongoing pain can literally speed up our biological clock.

Precisely. Chronic pain, by constantly activating inflammatory pathways, can influence epigenetic markers, which are essentially switches that turn genes on or off, thereby affecting cellular aging.

And what about the drugs that act on GABA receptors? Do they play a role in this aging or mortality picture?

That’s where the balance comes in. While these drugs can provide crucial pain relief, which in itself can slow down the biological aging accelerated by pain, there are also known risks. The long-term use of some GABAergic medications can carry risks of dependence, cognitive side effects, and even increased fall risk in older adults, indirectly impacting health and longevity.

So, it's a careful balancing act: managing pain to mitigate its aging effects, while also being mindful of the potential downsides of the interventions.

Absolutely. What’s still not fully established is whether treating chronic pain with GABAergic drugs directly reverses or slows epigenetic aging, or if the benefit is primarily from alleviating the pain's detrimental effects. That's an area of ongoing research.